ULTIMOVACS ASA ULTMF
ULTIMOVACS ASA ULTMF
Apertura: -
Variazione: -
Volumi: -
Minimo: -
Massimi: -
Distanza Mas/Min: -
Tipologia: Azioni
Ticker: ULTMF
ISIN: NO0010851603

Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation

  • 102

Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third quarter 2024 results, on Wednesday, November 6, 2024.

The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Wednesday, November 6, 2024. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast.

The report and presentation will be available on the company website from 07:00 CET the same day.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: [email protected]
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: [email protected]
Phone: +47 482 48632


 

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

ti?nf=MTAwMTAxMDM3NCM0MDE5Nzg3NzAjMjIwOTM5Mw==
Ultimovacs-ASA.png

Primary Logo

GlobeNewsWire
GlobeNewsWire

GlobeNewswire è una delle più grandi reti di distribuzione di newswire al mondo, specializzata nella distribuzione di comunicati stampa aziendali, informazioni finanziarie e contenuti multimediali a media, investitori e lettori di tutto il mondo.